Genentech, a member of the Roche Group, announced that the phase III IMvigor211 study that evaluated Tecentriq (atezolizumab) in people with locally advanced or metastatic urothelial cancer whose disease progressed during or after treatment with a platinum-based chemotherapy did not meet its primary endpoint of overall survival compared to chemotherapy.
A simple urine test devised by researchers at Stanford Medicine and the VA Palo Alto Health Care System can diagnose people with bladder cancer more accurately than current standard methods. The test also allows physicians to not only assess the cancer’s response to treatment but to predict whether immunotherapy or chemotherapy is likely to be most effective for each patient.
